Czarina N Behrends1, Ashley A Eggman, Sarah Gutkind, Marie P Bresnahan, Kyle Fluegge, Fabienne Laraque, Alain H Litwin, Paul Meissner, Shuchin J Shukla, Ponni V Perumalswami, Jeffrey Weiss, Brooke E Wyatt, Bruce R Schackman. 1. Department of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York (Drs Behrends and Schackman and Mss Eggman and Gutkind); New York City Department of Health & Mental Hygiene, Queens, New York (Ms Bresnahan and Drs Fluegge and Laraque); Albert Einstein College of Medicine, Bronx, New York (Drs Litwin and Shukla and Mr Meissner); Montefiore Medical Center, Bronx, New York (Drs Litwin and Shukla); Icahn School of Medicine at Mount Sinai, New York, New York (Drs Perumalswami and Weiss); and Mount Sinai Hospital, New York, New York (Dr Perumalswami and Ms Wyatt).
Abstract
OBJECTIVE: To estimate the cost of delivering a hepatitis C virus care coordination program at 2 New York City health care provider organizations and describe a potential payment model for these currently nonreimbursed services. DESIGN: An economic evaluation of a hepatitis C care coordination program was conducted using micro-costing methods compared with macro-costing methods. A potential payment model was calculated for 3 phases: enrollment to treatment initiation, treatment initiation to treatment completion, and a bonus payment for laboratory evidence of successful treatment outcome (sustained viral response). SETTING: Two New York City health care provider organizations. PARTICIPANTS: Care coordinators and peer educators delivering care coordination services were interviewed about time spent on service provision. De-identified individual-level data on study participant utilization of services were also used. INTERVENTION: Project INSPIRE is an innovative hepatitis C care coordination program developed by the New York City Department of Health and Mental Hygiene. MAIN OUTCOME MEASURES: Average cost per participant per episode of care for 2 provider organizations and a proposed payment model. RESULTS: The average cost per participant at 1 provider organization was $787 ($522 nonoverhead cost, $264 overhead) per episode of care (5.6 months) and $656 ($429 nonoverhead cost, $227 overhead, 5.7 months) at the other one. The first organization had a lower macro-costing estimate ($561 vs $787) whereas the other one had a higher macro-costing estimate ($775 vs $656). In the 3-phased payment model, phase 1 reimbursement would vary between the provider organizations from approximately $280 to $400, but reimbursement for both organizations would be approximately $220 for phase 2 and approximately $185 for phase 3. CONCLUSIONS: The cost of this 5.6-month care coordination intervention was less than $800 including overhead or less than $95 per month. A 3-phase payment model is proposed and requires further evaluation for implementation feasibility. Project INSPIRE's HCV care coordination program provides good value for a cost of less than $95 per participant per month. The payment model provides an incentive for successful cure of hepatitis C with a bonus payment; using the bonus payment to support HCV tele-mentoring expands HCV treatment capacity and empowers more primary care providers to treat their own patients with HCV.
OBJECTIVE: To estimate the cost of delivering a hepatitis C virus care coordination program at 2 New York City health care provider organizations and describe a potential payment model for these currently nonreimbursed services. DESIGN: An economic evaluation of a hepatitis C care coordination program was conducted using micro-costing methods compared with macro-costing methods. A potential payment model was calculated for 3 phases: enrollment to treatment initiation, treatment initiation to treatment completion, and a bonus payment for laboratory evidence of successful treatment outcome (sustained viral response). SETTING: Two New York City health care provider organizations. PARTICIPANTS: Care coordinators and peer educators delivering care coordination services were interviewed about time spent on service provision. De-identified individual-level data on study participant utilization of services were also used. INTERVENTION: Project INSPIRE is an innovative hepatitis C care coordination program developed by the New York City Department of Health and Mental Hygiene. MAIN OUTCOME MEASURES: Average cost per participant per episode of care for 2 provider organizations and a proposed payment model. RESULTS: The average cost per participant at 1 provider organization was $787 ($522 nonoverhead cost, $264 overhead) per episode of care (5.6 months) and $656 ($429 nonoverhead cost, $227 overhead, 5.7 months) at the other one. The first organization had a lower macro-costing estimate ($561 vs $787) whereas the other one had a higher macro-costing estimate ($775 vs $656). In the 3-phased payment model, phase 1 reimbursement would vary between the provider organizations from approximately $280 to $400, but reimbursement for both organizations would be approximately $220 for phase 2 and approximately $185 for phase 3. CONCLUSIONS: The cost of this 5.6-month care coordination intervention was less than $800 including overhead or less than $95 per month. A 3-phase payment model is proposed and requires further evaluation for implementation feasibility. Project INSPIRE's HCV care coordination program provides good value for a cost of less than $95 per participant per month. The payment model provides an incentive for successful cure of hepatitis C with a bonus payment; using the bonus payment to support HCV tele-mentoring expands HCV treatment capacity and empowers more primary care providers to treat their own patients with HCV.
Authors: Matthew J Press; Ryan Howe; Michael Schoenbaum; Sean Cavanaugh; Ann Marshall; Lindsey Baldwin; Patrick H Conway Journal: N Engl J Med Date: 2016-12-14 Impact factor: 91.245
Authors: Soumitri Barua; Robert Greenwald; Jason Grebely; Gregory J Dore; Tracy Swan; Lynn E Taylor Journal: Ann Intern Med Date: 2015-08-04 Impact factor: 25.391
Authors: Karen M Clements; Robin E Clark; Pavel Lavitas; Parag Kunte; Camilla S Graham; Elizabeth O'Connell; Kimberly Lenz; Paul Jeffrey Journal: J Manag Care Spec Pharm Date: 2016-06
Authors: Mark Brennan-Ing; Liz Seidel; Leslie Rodgers; Jerome Ernst; Doug Wirth; Daniel Tietz; Antonio Morretti; Stephen E Karpiak Journal: PLoS One Date: 2016-02-05 Impact factor: 3.240
Authors: Czarina N Behrends; Sarah Gutkind; Regan Deming; Kyle R Fluegge; Marie P Bresnahan; Bruce R Schackman Journal: J Urban Health Date: 2021-08 Impact factor: 5.801
Authors: Brooke Wyatt; Ponni V Perumalswami; Anna Mageras; Mark Miller; Alyson Harty; Ning Ma; Chip A Bowman; Francina Collado; Jihae Jeon; Lismeiry Paulino; Amreen Dinani; Douglas Dieterich; Li Li; Maxence Vandromme; Andrea D Branch Journal: Hepatology Date: 2021-12 Impact factor: 17.298
Authors: Sarah Gutkind; Laura E Starbird; Sean M Murphy; Paul A Teixeira; Lauren K Gooden; Tim Matheson; Daniel J Feaster; Mamta K Jain; Carmen L Masson; David C Perlman; Carlos Del Rio; Lisa R Metsch; Bruce R Schackman Journal: Drug Alcohol Depend Date: 2022-01-10 Impact factor: 4.852
Authors: Arpan A Patel; Aileen Bui; Eian Prohl; Debika Bhattacharya; Su Wang; Andrea D Branch; Ponni V Perumalswami Journal: Hepatol Commun Date: 2020-12-07